$42.770
+1.574 (+3.68%)Al cierre
Comparativa sectorial de TRAX
In the context of the broader market, TRAX competes directly with industry leaders such as KARD and TYRA. With a market capitalization of $1.48B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against KARD's N/A and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de First Tracks Biotherapeutics Inc
The company has experienced significant losses, with a net income of -33,374,000 USD in Q2 2026 and an EPS of -0.95. However, the current ratio has improved to 14.28, indicating better liquidity.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.